EXTENDED SPECTRUM β-LACTAMASES (ESBL) PRODUCING ENTEROBACTERIACEAE - CHALLENGE IN THE MEDICINE PRACTICE

The growing use of broad-spectrum cephalosporins in recent years resulted in the appearance of the ESBLs. The first extended β-lactamase, designated SHV-2, was reported inGermany in 1983. Since than more and more extended-spectrum β-lactamases have been detected across the world. The ESBLs are capable of hydrolyzing broad-spectrum cephalosporins and are inhibited by clavulanate and tazobactam. The purpose: to summarize the data on the detection, monitoring and epidemiology of ESBLs-producing Enterobacteriaceae in our hospital during 6 years period using phenotype methods. Results: E. coli ESBLs positive – 4.8%; K. pneumoniae – 13.2%; Proteus spp. – 2.8% respectively. Conclusions: K. pneumoniae is the most common ESBLs-producer, folowed by E. coli and Proteus spp.